Sleep disturbances are among the earliest and most common non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), often predating the classic motor syndrome by years. These 4-repeat tauopathies affect brainstem and subcortical structures critical for sleep-wake regulation, producing distinctive sleep biomarker signatures that can aid in differential diagnosis from synucleinopathies like Parkinson's disease and multiple system atrophy["@arnulf2024"].
Sleep disturbances are among the earliest and most common non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), often predating the classic motor syndrome by years. These 4-repeat tauopathies affect brainstem and subcortical structures critical for sleep-wake regulation, producing distinctive sleep biomarker signatures that can aid in differential diagnosis from synucleinopathies like Parkinson's disease and multiple system atrophy["@arnulf2024"].
This page provides comprehensive coverage of sleep-based biomarkers for CBS and PSP, including circadian rhythm markers, polysomnographic parameters, CSF and blood sleep-related molecules, and actigraphy-derived metrics. These biomarkers serve dual purposes: early detection of neurodegeneration and differentiation from mimics (particularly other atypical parkinsonian syndromes)[@boe2024].
Both CBS and PSP target brainstem nuclei involved in sleep regulation:
| Structure | Function | Effect of Tauopathy |
|-----------|----------|---------------------|
| Pedunculopontine Nucleus (PPN) | REM sleep generation, arousal | Reduced REM sleep, fragmented sleep |
| Substantia Nigra pars reticulata | Sleep-wake transitions | Sleep fragmentation, insomnia |
| Locus Coeruleus | Noradrenergic arousal, REM atonia | REM behavior disorder, fragmented sleep |
| Dorsal Raphe Nuclei | Serotonergic sleep modulation | Altered sleep architecture |
| Sublaterodorsal Nucleus | REM sleep atonia control | REM without atonia |
While both are 4R-tauopathies with sleep dysfunction, important distinctions exist[@schneberger2023]:
| Sleep Parameter | CBS | PSP | Differential Value |
|-----------------|-----|-----|---------------------|
| REM Sleep Behavior Disorder | 0-8% | 0-13% | Low (both rare vs synucleinopathies) |
| Periodic Limb Movements | 50-70% | 60-80% | Moderate |
| Sleep Efficiency | 60-75% | 50-65% | High (PSP more severe) |
| Slow-Wave Sleep | Moderately reduced | Severely reduced | High |
| REM Sleep Percentage | Normal to slightly reduced | Significantly reduced | High |
| Sleep Latency | Normal | Prolonged | Moderate |
| Total Sleep Time | 4-5 hours | 3-4 hours | High |
Melatonin secretion reflects circadian pacemaker function. In CBS/PSP[@luz2023]:
Cortisol rhythm disruption reflects hypothalamic-pituitary-adrenal axis involvement:
| Parameter | CBS | PSP | Control |
|-----------|-----|-----|---------|
| Cortisol awakening response | Reduced | Markedly reduced | Normal |
| Evening cortisol | Normal | Elevated | Normal |
| Cortisol decline ratio | Normal | Reduced | Normal |
Differential Value:
Ambulatory temperature monitoring reveals:
RSWA is the electrophysiological hallmark of REM behavior disorder[@clignet2023]:
| Metric | CBS | PSP | Interpretation |
|--------|-----|-----|----------------|
| Phasic EMG activity | 15-30% | 20-40% | Higher in PSP |
| Tonic chin EMG | Elevated | Markedly elevated | Both show loss of atonia |
| SWEM score | 10-15 | 15-25 | Quantifies RSWA severity |
Key Insight: RSWA is less common in CBS/PSP (<15%) than in synucleinopathies (70-90%), making its presence supportive of CBS/PSP diagnosis.
| Parameter | CBS | PSP | Healthy Control | Pathological Threshold |
|-----------|-----|-----|------------------|------------------------|
| Total Sleep Time | 240-300 min | 180-240 min | 360-420 min | <300 min |
| Sleep Efficiency | 60-75% | 50-65% | >85% | <70% |
| N1 Percentage | 15-25% | 20-35% | 5-10% | >20% |
| N2 Percentage | 45-55% | 40-50% | 45-55% | Variable |
| N3 Percentage | 10-15% | 5-10% | 15-20% | <10% |
| REM Percentage | 15-20% | 10-15% | 20-25% | <15% |
| WASO | 90-120 min | 120-180 min | 30-45 min | >90 min |
PLMs are highly prevalent in CBS/PSP:
Sleep-disordered breathing is common and impacts disease progression:
| Parameter | CBS | PSP | Clinical Significance |
|-----------|-----|-----|----------------------|
| AHI | 10-20 | 15-30 | Higher in PSP |
| ODI | 8-15 | 12-25 | Nocturnal hypoxia more severe in PSP |
| Central Apneas | 5-10% | 10-15% | More central apneas in PSP |
Note: Differentiate from MSA (higher AHI, more central apneas).
Orexin maintains wakefulness; deficiency occurs in tauopathies[@sartor2024]:
| Metric | CBS | PSP | MSA | Controls |
|--------|-----|-----|-----|----------|
| CSF orexin-A (pg/mL) | 200-280 | 150-250 | 180-260 | 250-350 |
| Percentage with deficiency | 15-25% | 25-35% | 20-30% | <5% |
Differential Value:
| Biomarker | Collection | CBS Pattern | PSP Pattern |
|----------|------------|--------------|--------------|
| 6-sulfatoxymelatonin | Overnight urine | Reduced 30% | Reduced 50% |
| Cortisol metabolites | 24-hour urine | Normal | Elevated evening |
| Urea | Night/AM ratio | Flattened | Flattened |
Ambulatory monitoring provides continuous sleep-wake patterns[@sopfi2024]:
| Parameter | CBS | PSP | Healthy Controls | Pathological |
|-----------|-----|-----|-------------------|---------------|
| Sleep onset latency | 30-45 min | 45-60 min | 10-20 min | >30 min |
| Wake after sleep onset | 60-90 min | 90-120 min | 20-30 min | >60 min |
| Sleep efficiency | 70-80% | 60-75% | >85% | <75% |
| Fragmentation index | 30-40 | 40-55 | <20 | >35 |
| Peak activity timing | Delayed 1-2h | Delayed 2-3h | Normal | Delayed |
Unlike synucleinopathies, RBD is rare in CBS/PSP[@schneberger2023]:
| Feature | CBS | PSP | Synucleinopathies |
|---------|-----|-----|-------------------|
| RBD prevalence | 0-8% | 0-13% | 70-90% |
| RSWA severity | Mild-moderate | Moderate | Severe |
| Dream enactment | Rare | Rare | Common |
| RBD before motor symptoms | Very rare | Very rare | Common (years) |
Clinical Implication: If RBD precedes CBS/PSP by >5 years, reconsider diagnosis (likely synucleinopathy).
iRBD is a strong marker for synucleinopathy:
| Category | Biomarker | Direction | Specificity |
|----------|-----------|-----------|-------------|
| Sleep Architecture | N3 percentage | ↓↓ | Moderate (PSP more severe) |
| Sleep Architecture | Sleep efficiency | ↓ | High |
| Circadian | Melatonin amplitude | ↓ | Moderate |
| Circadian | Cortisol evening | →/↑ | Moderate (PSP) |
| REM | RSWA severity | ↓ | High (vs synucleinopathy) |
| Movement | PLM index | ↑↑ | Moderate |
| CSF | Orexin | ↓ | Moderate |
| Category | Biomarker | Direction | Specificity |
|----------|-----------|-----------|-------------|
| Sleep Architecture | N3 percentage | ↓↓↓ | Very High |
| Sleep Architecture | Total sleep time | ↓↓↓ | Very High |
| Circadian | Melatonin amplitude | ↓↓↓ | High |
| Circadian | Cortisol evening | ↑ | Moderate |
| REM | REM latency | ↑↑ | High |
| Movement | PLM index | ↑↑↑ | Moderate |
| CSF | Orexin | ↓↓ | Moderate |
| Biomarker | CBS | PSP | Discrimination |
|-----------|-----|-----|----------------|
| Sleep efficiency | 60-75% | 50-65% | Moderate (PSP worse) |
| N3 percentage | 10-15% | 5-10% | High (PSP less) |
| Evening cortisol | Normal | Elevated | Moderate |
| PLM index | 30-50 | 40-70 | Low-moderate |
| Orexin | Mild reduction | Moderate reduction | Low |
Sleep biomarkers complement imaging and fluid biomarkers:
| Sleep Feature | CBS/PSP | PD |
|---------------|---------|-----|
| RBD prevalence | <15% | 70-90% |
| Sleep efficiency | 50-75% | 65-80% |
| PLM index | 30-70 | 15-25 |
| Orexin | Mildly reduced | Preserved |
| Sleep Feature | CBS/PSP | AD |
|---------------|---------|-----|
| RBD | Rare (<15%) | Rare (<10%) |
| Sleep efficiency | 50-75% | 65-80% |
| N3 | Severely reduced | Moderately reduced |
| Circadian | Phase delay | Flattened amplitude |
| Sleep Feature | CBS/PSP | MSA |
|---------------|---------|-----|
| RBD | <15% | 50-80% |
| Sleep efficiency | 50-75% | 55-70% |
| Central apneas | 5-15% | 15-30% |
| Stridor | Rare | 15-30% |
Sleep biomarkers offer a non-invasive, accessible window into CBS and PSP pathophysiology. Key signatures include reduced sleep efficiency, severely diminished slow-wave sleep (especially in PSP), rare RBD compared to synucleinopathies, and circadian rhythm disturbances. These biomarkers provide both diagnostic value (differentiating CBS/PSP from PD/MSA) and prognostic information (predicting progression and treatment response).
The multimodal sleep biomarker approach — combining actigraphy, polysomnography, and circadian-phase assessments — enables clinicians to characterize sleep dysfunction comprehensively and monitor treatment efficacy. As disease-modifying therapies emerge, sleep biomarkers may serve as sensitive outcome measures reflecting brainstem integrity.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses:
The following diagram shows the key molecular relationships involving Sleep Biomarkers for CBS and PSP discovered through SciDEX knowledge graph analysis: